- TumorGenesis president Richard Gabriel selected to feature as keynote presenter at inaugural Drug Discovery & Preclinical Virtual Summit
- The summit features over 150 delegates from across bio-pharmaceutical industry coming together to market sector’s latest breakthroughs
- TumorGenesis, which specializes in creating laboratory-grown cancer cells directed towards ovarian cancer research, recently announced its first sale of cancer cell culture media to US university
- The global cell culture media market set to grow to over $2.4 billion per annum by 2024
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has revealed that Richard Gabriel, President of POAI’s subsidiary TumorGenesis, presented at the upcoming Precision in Drug Discovery & Preclinical Virtual Summit on July 23, 2020 (http://ibn.fm/8N14a).
TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, announced earlier in June that the company had sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/yK35y). As one of the featured keynote speakers at the upcoming conference, Richard Gabriel is expected to elaborate on the company’s ongoing breakthroughs within the field of oncological research as well as its future growth ambitions.
The inaugural Precision in Drug Discovery & Preclinical Virtual Summit, hosted by Precision Evolution Global, will serve as a unique platform for members of the bio-pharmaceutical industry to network and collaborate in an effort towards furthering their discovery and scientific strategies. Featuring over 150 attendees spread across over 25 countries, the summit is set to showcase the recent progress and research trends within the pharma-biotech and academic space, including new compounds, drug design and synthesis methods in addition to the latest technological innovations within the field.
The virtual gathering will also feature a number of notable keynote addresses while simultaneously facilitating pre-scheduled meetings between potential collaborators and a host of reliable service providers, in an attempt to assist the summit’s attendees in procuring solutions to their most pressing research challenges in 2020 and beyond.
Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. The company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells to be used in assisting researchers and clinicians identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they feed into TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample, to enable the development of a patient-specific treatment plan (http://ibn.fm/6SRYp).
A recent study by MarketWatch has forecast that the global cell culture media market is expected to grow to a value of $2.36 billion by 2024, driven by an 8.4% compounded annual growth rate over the next 4 years (http://ibn.fm/L4ZVJ). TumorGenesis, which has thus far centered its focus on ovarian-specific formulations, has hopes of leveraging their current capabilities to expand the portfolio of tools and services the company can offer to cancer researchers. “We believe by helping researchers develop cells and tumors that more closely mimic cells and tumor found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” stated TumorGenesis President Richard Gabriel.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.